Cancer News and Research

Latest Cancer News and Research

Tax forms to include health insurance cost info -- per health law requirement

Today's headlines also include coverage of other health law issues, such as student health plans and the health care workforce.

31 Jan 2013

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Cell Therapeutics, Inc. (CTI) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.

31 Jan 2013

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).

31 Jan 2013

Researchers identify mechanism by which vancomycin resistance spreads between bacteria

Worldwide, many strains of the bacterium Staphyloccocus aureus, commonly known as staph infections, are already resistant to all antibiotics except vancomycin. But as bacteria are becoming resistant to this once powerful antidote, S. aureus has moved one step closer to becoming an unstoppable killer.

31 Jan 2013

Silibinin kills skin cells mutated by UVA radiation and protects against cancer

A pair of University of Colorado Cancer Center studies published this month show that the milk thistle extract, silibinin, kills skin cells mutated by UVA radiation and protects against damage by UVB radiation - thus protecting against UV-induced skin cancer and photo-aging.

31 Jan 2013

Interrupting key interaction between p68 and calcium-calmodulin inhibits cancer metastasis

Disrupting a key interaction between two types of proteins in cells inhibits the spread of cancerous cells, providing researchers with a new pathway toward developing cancer-fighting drugs, according to new findings by Georgia State University scientists.

31 Jan 2013

Erbin protein critical to brain excitement

Scientists have found an early step in how the brain's inhibitory cells get excited. A natural balance of excitement and inhibition keeps the brain from firing electrical impulses randomly and excessively, resulting in problems such as schizophrenia and seizures. However excitement is required to put on the brakes.

31 Jan 2013

Microscopic hematuria poor indicator for renal, bladder malignancy

The presence of microscopic levels of blood in the urine is unreliable as an indicator for renal or bladder cancer, report researchers.

30 Jan 2013

ALDH1 expression predicts outcome in node-negative rectal cancer

Expression of the cancer stem cell marker aldehyde dehydrogenase 1 is an independent predictor for poor prognosis in node-negative rectal cancer, researchers say.

30 Jan 2013

Inflammation could hinder energy intake in advanced cancer

Energy intake, particularly energy density, is positively associated with energy balance in patients with advanced cancer, report Swedish researchers.

30 Jan 2013

Scientists discover functional control strategies in emotional circuits of people with social phobia

Fear is a protective function against possible dangers that is designed to save our lives. Where there are problems with this fear mechanism, its positive effects are cancelled out: patients who have a social phobia become afraid of perfectly normal, everyday social situations because they are worried about behaving inappropriately or being thought of as stupid by other people.

30 Jan 2013

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.

From QIAGEN Manchester Limited 30 Jan 2013

Report calls for greater emphasis on preventive care

A report issued by the Trust for America's Health is urging a revamp of state and local public health efforts to better integrate and focus prevention strategies.

30 Jan 2013

UCSD molecular biologist to receive Charles Rodolphe Brupbacher Prize for Cancer Research

Molecular biologist Michael Karin is to receive this year's Charles Rodolphe Brupbacher Prize for Cancer Research in recognition of his studies on the role of chronic inflammation in the development of tumors. The award, which carries CHF 100,000 in prize money, is considered one of the highest accolades for cancer researchers worldwide. The awards ceremony takes place in Zurich this Thursday in the framework of an international symposium on "Breakthroughs in Cancer Research and Therapy".

30 Jan 2013

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Merck Serono, a division of Merck, Darmstadt, Germany, and The Feinstein Institute for Medical Research, announced today that they will collaborate to develop antibodies for the treatment of systemic lupus erythematosus (SLE).

30 Jan 2013

Researchers determine precise configuration of humulones

Researchers employing a century-old observational technique have determined the precise configuration of humulones, substances derived from hops that give beer its distinctive flavor.

30 Jan 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013